Cervical small-cell carcinoma

Unlabeled Uses Adrenocortical, bladder, cervical, endometrial, prostatic, testicular carcinomas Ewing s sarcoma multiple sclerosis non-small cell, small cell lung cancer organ transplant rejection osteosarcoma ovarian germ cell, primary brain, trophoblastic tumors rheumatoid arthritis soft tissue sarcomas systemic dermato-myositis systemic lupus erythematosus Wilms tumor... 

It is used for the treatment of non small cell lung carcinoma, breast carcinoma, Hodgkin s disease, ovarian carcinoma, squamous cell carcinoma of the head and neck, cervical squamous cell carcinoma, renal cell cancer and Kaposi s sarcoma. 

Qinkal uses Advanced ovarian carcinoma, node-positive breast cancer (adjuvant), metastatic breast cancer, non-small cell lung cancer, cervical, bladder, head and nedc cancer, AIDS-related Kaposi s sarcoma (second line). 

Human Lung Carcinoma Cell Line Human Cervical Carcinoma Human T-Cell Leukaemia Human Non Small Cell Lung Cancer Laryngeal Cancer Human Colon Cancer Human Colon Cancer... 

Human Cervical Carcinoma Human Non Small Cell Lung Cancer Melanoma... 

Carcinoids, atypical carcinoids, small cell carcinomas, and large cell NE carcinomas have been reported as primary cervical tumors.All small cell cervical carcinomas studied to date have been cytokeratin-positive, and more than 90% have been positive for EMA. Reactivity for CEA with polyclonal antisera occurs in 77%. Small cell cervical carcinomas are positive for CK20 or TTF-1 in 14.3% and 20% of cases, respectivelyWith respect to NE markers, NSE is present in 95%, synaptophysin in 46%, chromogranin A in 43%, and CD57 in 37%. Similar frequencies of positivity for NE markers have been reported in more recent studies.These tumors may also contain peptide and amine hormones including serotonin (31%), ACTH (23%), and somatostatin (8%). 

Stoler and associates demonstrated human papillomavirus 18 (HPV18) in 78% of small cell cervical carcinomas with NE differentiation. The presence of this papilloma subtype was five times more frequent than HPV-16 in the 20 cases studied. Ishida and cowork-ers ° found that of 10 small cell NE carcinomas of the... 

Extrapolating data from the cervical and pulmonary literature, assorted case reports, and reviews,it appears that small cell and large cell neuroendocrine carcinomas involving endometrium would express chromogranin, synaptophysin, neuron-specific enolase, and CD56 in a significant number of cases. The extent to which these endometrial neuroendocrine carcinomas can express TTF-1 and pi6 has not been studied extensively.It should be noted, however, that... 

Carlson JW, Nucci MR, Brodsky J, et al. Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas The role of TTF-1, WT-l and HPV analysis. Histopathol-ogy. 2007 51 305-312. 

Anthracyclines - Two reports of Phase II clinical trials with 4 -epido-xorubicin (4 -ED) in a variety of malignancies have appeared. The response rate in previously untreated breast cancer patients was 54%. Responses were also seen in endometrial carcinoma, cervical carcinoma, non-Hodgkins lymphoma, melanoma, and skin cancer.Only a single partial responder was seen in 34 evaluable cases of non-small cell lung... 

Cisplatin is used for the treatment of ovarian and cervical carcinomas small cell and non-small cell bronchial and lung carcinomas testicular, endometrial, bladder, and prostate carcinomas tumors of the head and throat as well as sarcomas and melanomas. The treatment with cisplatin is complicated by the presence of considerable side effects, whereby the high nephrotoxicity is an especially dosage-limiting factor. Other side effects include hair loss, a reduction of leukocytes and thrombocytes (anemia), an impairment of the taste and hearing senses, as well as nausea and vomiting. 

The efficacy of iproplatin for the treatment of ovarian cancer, small cell lung carcinomas, and advanced squamous cervical carcinomas has been evaluated in the United States and in Great Britain. 

The possible modes of action of 4HPR have been mostly investigated in already transformed tumor cells. 4HPR suppressed the proliferation of cell lines of different tumor types such as human breast carcinoma [24-27], prostate adenocarcinoma [28, 29], leukemias [30, 31], neuroblastoma [32, 33, 34], ovarian carcinoma [35, 36], cervical carcinoma [37, 38], head and neck squamous cell carcinoma [39], esophageal squamous carcinoma [40] and small-cell lung can-... 

Hietanen, S., et al., Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA, 2000, 97(15), 8501-6. 

---